Capnography-detected respiratory depression during procedural sedation with remimazolam versus propofol: a randomised trial.

ABSTRACT: Remimazolam, a novel ultra-short-acting benzodiazepine, has gained attention for its favourable safety profile, particularly its reduced risk of respiratory depression compared to propofol during procedural sedation. However, previous studies have primarily relied on visual assessment or pulse oximetry, which may underestimate the incidence of respiratory compromise. In this prospective randomized controlled trial, we compared the respiratory effects of remimazolam and propofol using continuous capnography monitoring, a more sensitive method for detecting hypoventilation and apnoea. Seventy adult patients undergoing procedural sedation were randomly assigned to receive either remimazolam with remifentanil or propofol with remifentanil. The primary outcome was the frequency of respiratory d

SUBMITTER: Kim J 

PROVIDER: S-EPMC12647873 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature